DR. RODGER PAUL MCEVER, M.D.
Medical Practice at 13 St, Oklahoma City, OK
License number
Oklahoma 16359
Category
Medical Practice
Type
Specialist
Address
Address
825 NE 13Th St, Oklahoma City, OK 73104
Phone
(405) 271-6480
(405) 271-3137 (Fax)
(405) 271-3137 (Fax)
Personal information
See more information about RODGER PAUL MCEVER at radaris.comName
Address
Phone
1716 Guilford Ln, Nichols Hills, OK 73120
Oklahoma City, OK
1716 Guilford Ln, Nichols Hills, OK 73120
Professional information
Dr. Rodger P Mcever, Oklahoma City OK - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
825 NE 13Th St, Oklahoma City 73104
(405) 271-6480 (Phone), (405) 271-3137 (Fax)
(405) 271-6480 (Phone), (405) 271-3137 (Fax)
Languages:
English
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1974
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1974
Synthetic Glycosulfopeptides And Methods Of Synthesis Thereof
US Patent:
6569998, May 27, 2003
Filed:
May 4, 2001
Appl. No.:
09/849031
Inventors:
Richard D. Cummings - Edmond OK
Rodger P. McEver - Oklahoma City OK
Rodger P. McEver - Oklahoma City OK
Assignee:
Board of Regents of the University of Oklahoma
International Classification:
C07H 306
US Classification:
530395, 530324, 530325, 530326, 530327, 530322, 530333, 530344, 530402, 530412, 514 25, 514 23, 514 42, 514 8
Abstract:
A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewis group or a sialyl Lewis group. In a preferred version the GSPs have an O-glycan comprising a 1,6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.
Synthetic Glycosulfopeptides And Methods Of Synthesis Thereof
US Patent:
6545123, Apr 8, 2003
Filed:
May 4, 2001
Appl. No.:
09/849562
Inventors:
Richard D. Cummings - Edmond OK
Rodger P. McEver - Oklahoma City OK
Rodger P. McEver - Oklahoma City OK
Assignee:
Board of Regents of the University of Oklahoma
International Classification:
A61K 3814
US Classification:
530322, 530395, 530324, 530325, 530326, 530327, 530328, 530329, 530333, 530402, 435 691, 514 21, 514 23, 514 25
Abstract:
A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewis group or a sialyl Lewis group. In a preferred version the GSPs have an O-glycan comprising a 1, 6 linkage to a GalNAc. The present invention further contemplates in vitro methods of the synthesis of these GSPs without the use of the cells and methods of their use in vivo as powerful anti-inflammatory antithrombotic, or anti-metastatic compounds. The invention also contemplates a method of synthesizing oligosaccharides by cleaving the glycan from the GSP.
Anti-P-Selectin Antibodies And Methods Of Their Use And Identification
US Patent:
2011028, Nov 24, 2011
Filed:
Aug 5, 2011
Appl. No.:
13/204508
Inventors:
Scott Rollins - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US
International Classification:
A61K 39/395, A61P 37/06, A61P 11/06, A61P 29/00, A61P 17/06
US Classification:
4241391
Abstract:
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Anti-P-Selectin Antibodies And Methods Of Their Use And Identification
US Patent:
2011029, Dec 1, 2011
Filed:
Dec 21, 2010
Appl. No.:
12/974739
Inventors:
Scott Rollins - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US
International Classification:
A61K 39/395, C07H 21/04, A61P 7/00, C12N 1/19, C12N 1/15, C07K 16/28, C12N 5/10
US Classification:
4241391, 5303879, 5303873, 536 2353, 435331, 43525421, 4352544, 4352543
Abstract:
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Method For Inhibiting An Inflammatory Response Using Antibodies To P-Selectin Glycoprotein Ligand
US Patent:
6309639, Oct 30, 2001
Filed:
Aug 9, 2000
Appl. No.:
9/635297
Inventors:
Richard D. Cummings - Edmond OK
Kevin L. Moore - Oklahoma City OK
Rodger P. McEver - Oklahoma City OK
Kevin L. Moore - Oklahoma City OK
Rodger P. McEver - Oklahoma City OK
Assignee:
The Board of Regents of the University of Oklahoma
International Classification:
A61K 39395, C07K 1628
US Classification:
4241431
Abstract:
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [. sup. 3 H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
Soluble Form Of Gmp-140
US Patent:
5767241, Jun 16, 1998
Filed:
Jul 8, 1994
Appl. No.:
8/272224
Inventors:
Rodger P. McEver - Oklahoma City OK
Assignee:
The Board of Regents of The University of Oklahoma - Norman OK
International Classification:
C07K 1400, C12N 1509
US Classification:
530350
Abstract:
The invention is directed to a purified soluble form of human granule membrane protein 140 (GMP-140) which lacks an amino acid sequence comprising a transmembrane domain and which is effective in inhibiting leukocyte adherence mediated by granule membrane protein 140. Nucleic acid encoding the soluble form of GMP-140 is disclosed.
Stem Cells Treated By In Vitro Fucosylation And Methods Of Use
US Patent:
8084255, Dec 27, 2011
Filed:
Feb 17, 2010
Appl. No.:
12/707481
Inventors:
Lijun Xia - Edmond OK, US
Rodger P. McEver - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
C12N 5/08
US Classification:
435372
Abstract:
A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e. g. , α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.
Anti-P-Selectin Antibodies And Methods Of Using The Same To Treat Inflammatory Diseases
US Patent:
8377440, Feb 19, 2013
Filed:
Nov 30, 2007
Appl. No.:
12/516987
Inventors:
Rodger P. McEver - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Ziad Kawar - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Ziad Kawar - Oklahoma City OK, US
Assignee:
Selexys Pharmaceuticals Corporation - Oklahoma City OK
Oklahoma Medical Research Foundation - Oklahoma City OK
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
A61K 39/395, C07K 16/00
US Classification:
4241331, 8303871, 8303887, 4241731
Abstract:
The invention features antibodies, e. g. , chimeric and humanized antibodies, that recognize (i. e. , bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e. g. , sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.
Cells Treated By In Vitro Fucosylation And Methods Of Production And Use Thereof
US Patent:
2013025, Sep 26, 2013
Filed:
May 14, 2013
Appl. No.:
13/894123
Inventors:
Lijun Xia - Edmond OK, US
Rodger P. McEver - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
A61K 35/28
US Classification:
424 937, 435375
Abstract:
A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed.